Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
Trial Parameters
Brief Summary
The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer.
Eligibility Criteria
Inclusion Criteria: * Age of 20-85 years, with ECOG performance 0-2. * Thoracic esophageal cancer with clinical stage I-IV and biopsy proof; patient with stage I-IV cervical esophageal cancer could be recruited in this trial according to Investigator's assessment. * Complete CCRT with total doses of 45-55Gy to GTV via external beam radiotherapy (EBRT). Exclusion Criteria: * According to Investigator's assessment, patients with double cancer or recurrence could be recruited in this trial if they continue to receive systemic therapy. * Patient with double cancer, esophageal cancer or recurrence who is scheduled for surgery treatment. * Involvement of tracheal mucosa or bronchial mucosa. * Stenosis of esophageal lumen that cannot be bypassed by the applicator after EBRT. * The distribution of the lesions of interest exceeds 10cm range. * The patient is participating in other clinical trials.